Cited by 127Treatment of Major DepressionBipolar Disorder and TreatmentMental Health Treatment and Access

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

Boulenger, Jean-Philippe, Loft, Henrik, Florea, Ioana·2012·Journal of Psychopharmacology

Open this paper in CoChat — free account

Abstract

The efficacy and tolerability of Lu AA21004 in the prevention of relapse of major depressive disorder (MDD) in patients in remission after acute treatment was evaluated. Patients ( n=639) aged 18–75 years with a primary diagnosis of MDD with a current major depressive episode (MDE) ≥4 weeks’ duration, at least one prior MDE and a MADRS total score ≥26 received 12-week, open-label Lu AA21004 at 5 or 10mg/day. Patients in remission (MADRS ≤10) at both weeks 10 and 12 were assigned to double-blind treatment with either placebo or Lu AA21004 (fixed dose from Week 8).Patients (n=396) were treated, after random assignment to placebo (n=192) or Lu AA21004 (n=204). The primary analysis of time to relapse (full-analysis set, Cox proportional hazard model) showed a statistically significant difference in favour of Lu AA21004 versus placebo with a hazard ratio of 2.01 (95% confidence interval: 1.26–3.21; p=0.0035). The proportion of patients who relapsed was 13% in the Lu AA21004 group ( n=27) and 26% in the placebo group ( n=50). The withdrawal rates due to adverse events were 8% (open-label), and 3% (placebo) and 8% (Lu AA21004) (double-blind). Thus, Lu AA21004 was effective in preventing relapse of MDD and was well tolerated as maintenance treatment.

Integrity signals

Registry

Crossref · 10.1177/0269881112441866

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Untitled work
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 2×
“When compared with the results of a meta-analysis based on seven clinical trials using a relapse-prevention design with placebo substitution after a one to two month open-label antidepressant treatment of MDD followed by a six-month relapse prevention period (Geddes et al., 2003), our results appear to be similar for…”
BackgroundResult
Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Are Subjects in Pharmacological Treatment Trials of Depression Representative of Patients in Routine Clinical Practice?
Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.469 · Cited by 382

Show all 22 references

Research works printed but not linked: 2

Adell A, 2010, Drugs, 13, 900
Mørk A, 2011, Biol Psychiatry, 69, 186S

Sorted by citations

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 663
Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang‐Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 247
Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Self-citation
Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction
Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143
“, 2012) and in relapse prevention (Boulenger et al., 2012).”
Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome, L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 141
The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants
Köhler, S., Cierpinsky, K., Kronenberg, G., & Adli, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609072 · Cited by 140
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
Mahableshwarkar, A. R., Jacobsen, P. L., & Chen, Y. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761600 · Cited by 137
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136
A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder*
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
Jacobsen, P. L., Mahableshwarkar, A. R., Chen, Y., Chrones, L., & Clayton, A. H. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12980 · Cited by 123
Vortioxetine (brintellix): a new serotonergic antidepressant.
(2015) · PubMed Central · Cited by 112
Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10744 · Cited by 100
Self-citation
A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., Serenko, M., & Trivedi, M. H. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3839-0 · Cited by 98
Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Vortioxetine: a New Treatment for Major Depressive Disorder
Connolly, K. R., & Thase, M. E. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1133588 · Cited by 92
Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Alvarez, E., Artigas, F., & Perez, V. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41387 · Cited by 84
The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram
Vieta, E., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.053 · Cited by 72
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
Baldwin, D. S., Hansen, T. F., & Florea, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.725035 · Cited by 73
Self-citation
Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder
Pae, C., Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Serretti, A. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140120 · Cited by 71
Vortioxetine for depression in adults
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011520.pub2 · Cited by 69
Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine – a quantitative EEG study in rats
Leiser, S. C., Pehrson, A. L., Robichaud, P. J., & Sánchez, C. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12782 · Cited by 63
Vortioxetine: First Global Approval
Gibb, A. D., & Deeks, E. D. (2013) · Drugs · doi:10.1007/s40265-013-0161-9 · Cited by 66
Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder
Al-Sukhni, M., Maruschak, N. A., & McIntyre, R. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1046836 · Cited by 59
New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
Katona, C., & Katona, C. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39544 · Cited by 59
A Review of Novel Antidepressants: A Guide for Clinicians
Faquih, A. E., Memon, R. I., Hafeez, H., Zeshan, M., & Naveed, S. (2019) · Cureus · doi:10.7759/cureus.4185 · Cited by 58
A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder
Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Simon, J. S. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12328 · Cited by 50
A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine
Deardorff, W. J., & Grossberg, G. T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.960842 · Cited by 49
Vortioxetine: A Review of Its Use in Major Depressive Disorder
Garnock-Jones, K. P. (2014) · CNS Drugs · doi:10.1007/s40263-014-0195-x · Cited by 49
Randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder
Nishimura, A., Aritomi, Y., Sasai, K., Kitagawa, T., & Mahableshwarkar, A. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12565 · Cited by 45
A randomized, double‐blind, fixed‐dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder
Mahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., & Chen, Y. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2371 · Cited by 44
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial
Jacobsen, P. L., Zhong, W., Nomikos, G. G., & Clayton, A. H. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.06.018 · Cited by 43
A Review of Antidepressant Therapy in Primary Care
Kennedy, S. H. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01420 · Cited by 41
Vortioxetina: una nueva alternativa en el trastorno depresivo mayor
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2017) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2017.06.006 · Cited by 42
The US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine
Zhang, J., Mathis, M. V., Sellers, J. W., Kordzakhia, G., Jackson, A. J., Dow, A. L., Yang, P., Fossom, L. H., Zhu, H., Patel, H., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09164 · Cited by 38
An Overview of Vortioxetine
Schatzberg, A. F., Blier, P., Culpepper, L., Jain, R., Papakostas, G. I., & Thase, M. E. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14027ah1 · Cited by 36
Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation
Cosgrove, L., Vannoy, S. D., Mintzes, B. J., & Shaughnessy, A. F. (2016) · Accountability in Research · doi:10.1080/08989621.2016.1153971 · Cited by 32
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
Bobo, W. V., Kelliny, M., Croarkin, P. E., & Moore, K. M. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s55313 · Cited by 33
Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder
Vieta, E., Loft, H., & Florea, I. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.012 · Cited by 30
Self-citation
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies
Llorca, P., Lançon, C., Brignone, M., Rive, B., Salah, S., Ereshefsky, L., & François, C. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.969566 · Cited by 31
Vortioxetine: A new alternative for the treatment of major depressive disorder
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2018) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.02.005 · Cited by 28
Cognitive dysfunctions in depression – underestimated symptom or new dimension?
Jarema, M., Dudek, D., & Czernikiewicz, A. (2014) · Psychiatria Polska · doi:10.12740/pp/31215 · Cited by 29
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma
Christensen, M. C., Florea, I., Loft, H., & McIntyre, R. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.074 · Cited by 26
Self-citation
Vortioxetine for the Treatment of Depression
Pearce, E. F., & Murphy, J. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014528305 · Cited by 27
Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
Citrome, L., DiBernardo, A., & Singh, J. B. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 27
New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine
Orsolini, L., Tomasetti, C., Valchera, A., Iasevoli, F., Buonaguro, E. F., Vellante, F., Fornaro, M., Fiengo, A. L. C., Mazza, M., Vecchiotti, R., et al. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1173545 · Cited by 26
The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis
Fu, J., & Chen, Y. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3633-z · Cited by 24
The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
McIntyre, R. S. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150589 · Cited by 23
Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database
Subeesh, V., Singh, H., Maheswari, E., & Beulah, E. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.09.005 · Cited by 21
Vortioxetine for the treatment of major depressive disorder
Tritschler, L., Felice, D., Colle, R., Guilloux, J., Corruble, E., Gardier, A. M., & David, D. J. P. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.950655 · Cited by 23
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland
Soini, E. J., Hallinen, T., Brignone, M., Campbell, R., Diamand, F., Cure, S., Aalto-Setälä, M., Danchenko, N., Koponen, H., & Kolasa, K. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1240617 · Cited by 20
Suicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II
Baldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw092 · Cited by 20
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies
Mattingly, G. W., Necking, O., Schmidt, S. N., Reines, E. H., & Ren, H. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2178082 · Cited by 20
Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study
Thase, M. E., Jacobsen, P. L., Hanson, E., Xu, R., Tolkoff, M., & Murthy, N. V. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.002 · Cited by 18
Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves
Zhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 13
Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder
Dubovsky, S. L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.904286 · Cited by 14
A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder
Naik, H., Chan, S., Vakilynejad, M., Chen, G., Loft, H., Mahableshwarkar, A. R., & Areberg, J. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12513 · Cited by 13
Self-citation
Depression and Cerebrovascular Disease: Could Vortioxetine Represent a Valid Treatment Option?
Carta, M. G., Pala, A. N., Finco, G., Musu, M., & Moro, M. F. (2015) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901511010144 · Cited by 12
Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test
Refsgaard, L. K., Haubro, K., Pickering, D. S., Stuart, S. A., Robinson, E. S. J., & Andreasen, J. T. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4407-6 · Cited by 13
Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
Durgam, S., Chen, C., Migliore, R., Prakash, C., & Thase, M. E. (2019) · Depression and Anxiety · doi:10.1002/da.22872 · Cited by 11
Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine
Lachaîne, J., Beauchemin, C., Bibeau, J., Patenaude, J., Chokka, P. R., Proulx, J., & Bougie, J. K. (2019) · CNS Spectrums · doi:10.1017/s1092852919000853 · Cited by 11
On assessing potential efficacy for vortioxetine in generalized anxiety disorder
Baldwin, D. S., & Nutt, D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.018 · Cited by 11
Vortioxetine: a review of new antidepressant
Mohr, P., Melicher, T., & Knytl, P. (2016) · Psychiatrie pro praxi · doi:10.36290/psy.2016.009 · Cited by 9
Green Adsorptive Stripping Electrochemical Methods for Determination of Vortioxetine Hydrobromide at Graphite Pencil Electrode
Elhenawee, M., Saleh, H., Hussien, E. M., & Derar, A. R. (2020) · IEEE Sensors Journal · doi:10.1109/jsen.2020.2997738 · Cited by 9
Vortioxetine in the treatment of major depressive disorder
Baldwin, D. S., & Hanumanthaiah, V. B. (2015) · Future Neurology · doi:10.2217/fnl.14.69 · Cited by 9
A Comprehensive Review on Major Depressive Disorder: Exploring Etiology, Pathogenesis and Clinical Approaches
Mehra, A., Khanna, J., Singh, G., Sachdeva, V., & Bedi, N. (2025) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-025-00308-y · Cited by 8
Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
Montano, C. B., Jackson, W. C., Vanacore, D., & Weisler, R. H. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s337703 · Cited by 8
Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis
Zaccoletti, D., Mosconi, C., Gastaldon, C., Benedetti, L., Gottardi, C., Papola, D., Ponzi, O., Purgato, M., Naudet, F., Cristea, I. A., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00330-x · Cited by 12
A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
Bose, R., Hamdani, S. U., Minhas, F. A., & Herr, K. J. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2031146 · Cited by 7
When to stop medication in unipolar depression: A systematic review and a meta-analysis of randomized controlled trials
Arıkan, M. K., İlhan, R., Pogarell, O. M., & Metin, B. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.024 · Cited by 6
Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
Mills, N. T., Sampson, E., Fourrier, C., & Baune, B. T. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa092 · Cited by 6
Overview of approved psychiatric medications 2008-2023: A systematic review
IsHak, W. W., Totlani, J., Murphy, N., Renteria, S., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Khan, R., Chandy, T., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0705 · Cited by 5
The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine
François, C., Nielsen, R. Z., Danchenko, N., Williams, V. S. L., & Lançon, C. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1299701 · Cited by 5
Systematic review of gender bias in vortioxetine clinical trials
Santos-Casado, M., Guisado-Gil, A. B., & Santos‐Ramos, B. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110088 · Cited by 5
Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials
Gao, S., Xie, X., Fan, L., & Zhang, D. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12214 · Cited by 5
The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature
Weiss, F., Pacciardi, B., D’Alessandro, G., Caruso, V., Maremmani, I., Pini, S., & Perugi, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020531 · Cited by 4
Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study
Adair, M., Bose, R., & Schmidt, S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2382773 · Cited by 3
La vortioxétine : un nouvel antidépresseur pour traiter les épisodes dépressifs caractérisés
Colle, R., & Corruble, E. (2015) · L Encéphale · doi:10.1016/j.encep.2015.07.007 · Cited by 6
Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder
Liu, M. T. (2015) · World Journal of Pharmacology · doi:10.5497/wjp.v4.i1.17 · Cited by 4
Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries
Tegin, C., Tegin, G., & El‐Mallakh, R. S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4559 · Cited by 4
Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
Bai, W., Song, H., Hu, Y., Zhang, X., Wang, X., Guo, C., Qiu, B., & Dong, Z. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s428771 · Cited by 3
Vortioxetine versus reuptake inhibitors in adults with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials
Barbosa, E. C., da Silva, G. H. S., Sbardelotto, Â. E. E., Barroso, D. C., de Lima, F. R., Paez, L. E. F. E., Lança, S. B., Petrucci, A. B. C., Guimarães, F. B. D. M., & Nascimento, A. L. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104222 · Cited by 3
Vortioxetine (Brintellix®) and Levomilnacipran (Fetzima®): The Two Newest Additions to the Antidepressant Formulary
Roman, M. W., & Wilkinson, S. M. (2014) · Issues in Mental Health Nursing · doi:10.3109/01612840.2014.955155 · Cited by 3
A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study
Jacobsen, P. L., Zhong, W., Xu, R., & Nomikos, G. G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.090 · Cited by 3
Impact of Vortioxetine on severity, cognitive dysfunctions, and functionality in patients with major depression: a real world experience from Pakistan
Minhas, F. A., Rana, R. Z., Hamdani, S. U., & Rana, M. H. (2021) · Journal of Pakistan Psychiatric Society · doi:10.63050/jpps.18.01.87 · Cited by 3
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3
Donepezil and α‐synuclein Constipation: A 60 Month Follow-Up
Lepkowsky, C. M. (2022) · POJ Clinical Case Reports · doi:10.32648/2639-3298/4/1/1 · Cited by 2
Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder
Cuomo, A., Barillà, G., Cattolico, M., Pardossi, S., Mariantoni, E., Koukouna, D., Carmellini, P., & Fagiolini, A. M. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2333394 · Cited by 2
The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly
Deardorff, W. J., & Grossberg, G. T. (2015) · Current Geriatrics Reports · doi:10.1007/s13670-015-0140-y · Cited by 2
Review of a New Multimodal Antidepressant Vortioxetine
Oppa, M., Cesnekova, D., Nosalova, G., & Ondrejka, I. (2016) · Acta Medica Martiniana · doi:10.1515/acm-2016-0011 · Cited by 3
Vortioxetine: a comprehensive update on a new-generation antidepressant
Evren, C. (2021) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2021.00115 · Cited by 2
A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
Ng, C. G., Abousheishaa, A. A., Low, S.-Y., Zainal, N. Z., Thong, K. S., Awaluddin, A., Loo, T. H., Yacob, S., Jaafar, N. R. N., Taib, N. I. A., et al. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.8.2583 · Cited by 1
Donepezil and α-synuclein Constipation: A 36 Month Follow-Up
Lepkowsky, C. M. (2019) · POJ Clinical Case Reports · doi:10.32648/2639-3298/2/1/002 · Cited by 2

Authors: Boulenger, J.-P., Loft, H., & Florea, I.
Affiliations: Université Montpellier 1 (FR)
Lundbeck (Denmark) (DK)
ORCID: Florea, Ioana
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2012-04-09
Volume: 26
Issue: 11
Pages: 1408-1416
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881112441866
OpenAlex: W2066283885
Semantic Scholar: 09b9fc5799e896bbdda5703b74a14db0438fa09a
Cited by: 127
References: 22
Citations by year: 2026: 4 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 2 · 2017: 10 · 2016: 12 · 2015: 25 · 2014: 18 · 2013: 7 · 2012: 5
FWCI: 12.91
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: H. Lundbeck A/S
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords: vortioxetine, major depressive disorder, relapse prevention, maintenance therapy, antidepressant efficacy, drug tolerability, time to relapse, remission, adverse events
MeSH terms: Vortioxetine, Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Piperazines, Sulfides, Proportional Hazards Models, Treatment Outcome, Secondary Prevention, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks